Want to see UPB full AI Analyst Report?

Upstream Bio, Inc. (UPB) Price & Analysis

267 Followers

UPB Stock Chart & Stats

$6.41

>-$0.01(-0.16%)

At close: Jul 27 4:00 PM EDT

$6.41

>-$0.01(-0.16%)

Day’s Range― - ―

52-Week Range$5.85 - $33.68

Previous Close$6.3

Volume459.48K

Average Volume (3M)586.81K

Market Cap

$378.47M

Enterprise Value$117.26

Total Cash (Recent Filing)$261.31M

Total Debt (Recent Filing)$954.00K

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Nov 05, 2026

EPS Estimate

-0.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.90

Shares Outstanding54,771,040

10 Day Avg. Volume463,820

30 Day Avg. Volume586,814

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)4.30

Price to Sales (P/S)512.30

P/FCF Ratio-10.97

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$32.80

Price Target Upside411.70% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-2.88

Revenue Forecast (FY)$2.78M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low leverage and meaningful positive equity (~$271M) provide durable financial flexibility for an R&D-intensive biotech. This reduces near-term liquidity risk, supports continued clinical spending without immediate distress, and increases optionality for partnerships or staged financing.

Advancing Clinical Program (Phase 3 Readiness)Progressing toward Phase 3 with scheduled FDA end-of-Phase-2 interactions and >500 trial participants materially de-risks development versus earlier stages. Compelling Phase 2 results and CMC/device progress improve the company’s odds of regulatory success and future commercialization options over the coming months.

Governance And Oversight ContinuityRecent board elections and ratification of PricewaterhouseCoopers reinforce governance continuity and external oversight. Stable governance and a reputable auditor support credible financial reporting, regulatory interactions, and institutional partner confidence during critical late-stage development.

Bears Say

High Cash BurnSustained negative operating and free cash flow of roughly -$136M TTM indicates material runway pressure. The company will likely need external funding or significant spending reductions in the medium term, raising dilution or refinancing risk that can alter strategic flexibility.

Very Small And Declining RevenueWith revenue near $3.2M TTM and recent decline, current commercial receipts are insufficient to offset R&D and G&A. Until a product reaches market or licensing generates material revenue, the firm’s operating model remains dependent on external capital, limiting earnings resiliency.

Deep Negative Profitability And Weak ReturnsLarge recurring net losses (~-$156.5M TTM) and a deeply negative ROE (~-44%) signal that current operations erode shareholder capital. Continued negative profitability can deplete equity over time absent funding or successful commercialization, constraining long-term value creation.

Upstream Bio, Inc. News

Upstream Bio price target lowered to $25 from $43 at Truist

Truist lowered the firm’s price target on Upstream Bio (UPB) to $25 from $43 and keeps a Buy...

4d ago

UPB

Upstream Bio reports Q2 revenue $773,000, consensus $377,250

“We continued to make progress toward the initiation of our Phase 3 trials in severe asthma and CRSwNP...

4d ago

UPB

Matt Phipps Initiates Buy on Upstream Bio, Citing Favorable FDA Progress and Best-in-Class Potential for Verekitug

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today....

4d ago

UPB

UPB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Upstream Bio, Inc. (UPB) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street...

5d ago

UPB

Upstream Bio management to meet with Piper Sandler

Meeting to be held in New York on June 23 hosted by Piper Sandler. Published first on TheFly...

2M ago

UPB

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

Upstream Bio (UPB) presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with...

2M ago

UPB

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Upstream Bio (UPB) to Neutral from Overweight with a price target of $8, down from $35....

2M ago

UPB

Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor

An announcement from Upstream Bio, Inc. ( ($UPB) ) is now available. Upstream Bio, Inc. held its 2026...

2M ago

UPB

Upstream Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield initiated coverage of Upstream Bio (UPB) with a Buy rating and $36 price...

2M ago

UPB

Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target

Kate Dellorusso, an analyst from LifeSci Capital, maintained the Buy rating on Upstream Bio, Inc.. The associated price...

3M ago

UPB

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

Upstream Bio (UPB) presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic...

3M ago

UPB

Upstream Bio price target lowered to $50 from $51 at Mizuho

Mizuho lowered the firm’s price target on Upstream Bio (UPB) to $50 from $51 and keeps an Outperform...

3M ago

UPB

Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today....

3M ago

UPB

Upstream Bio reports Q1 revenue $1.03M, consensus $347,170

“We continue to make strong progress advancing our clinical programs in severe asthma and CRSwNP to position verekitug...

3M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $5.85 and its highest was $33.68 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $378.47M.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.

How were Upstream Bio, Inc.’s earnings last quarter?

Upstream Bio, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.726 by -$0.004.

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.73.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 54,771,040 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Upstream Bio, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.726. Following the earnings report the stock price went down -4.704%.

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Upstream Bio, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-33.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Historic Earnings Reports

UPB Stock 12 Month Forecast

Average Price Target

$32.80

▲(411.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.31,11.593846153846155,16.877692307692307,22.161538461538463,27.445384615384615,32.729230769230774,38.01307692307692,43.29692307692308,48.580769230769235,53.86461538461539,59.14846153846155,64.43230769230769,69.71615384615384,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.31,8.347692307692308,10.385384615384615,12.423076923076923,14.46076923076923,16.498461538461537,18.536153846153844,20.57384615384615,22.61153846153846,24.649230769230766,26.686923076923073,28.72461538461538,30.76230769230769,{"y":32.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.31,6.516923076923076,6.723846153846154,6.93076923076923,7.137692307692308,7.344615384615384,7.5515384615384615,7.758461538461538,7.9653846153846155,8.172307692307692,8.37923076923077,8.586153846153845,8.793076923076923,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >